HUTCHMED (China) Limited ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $548.5M-13.0% YoYTTM through 31 Dec 2025
Net Income $456.9M+1,111.0% YoYTTM through 31 Dec 2025
Free Cash Flow -$78.8MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 38.7% |
| EBITDA Margin | -4.7% |
| Operating Margin | -10.0% |
| Net Margin | 83.3% |
Returns
36.9%ROE
26.1%ROA
Balance Sheet Health
Debt / Equity0.08x
Current Ratio4.96x
Net Debt$21.8M
Cash & Equivalents$71.3M
Quality Metrics
Altman Z-Score3.72
Piotroski F-Score4 / 9
FCF Margin-14.4%
Rule of 40-3.8
Multi-Year Trend
RevenueFY2025: $548.5M
Diluted EPS$0.52TTMFY2025: $0.52
Dividend
No dividend
Capital Allocation
R&D Spend$148.3M
Capex Intensity2.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Oncology/Immunology | $285.5M | -21.4% | View details2026 Oncology/Immunology consolidated revenue guidance is set in the range of $330 million to $450 million. |
| Other Ventures | $263M | -1.4% | View detailsExpected to remain steady with lower equity earnings contribution from SHPL following the partial divestment. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.